Companies · Biotechnology

SeeLife Impact 5 LLCNew on the radar

DRAPER · Biotechnology

Diligence memoA one-page analyst read on SeeLife Impact 5 LLC — recommendation, valuation, rhythm, risks.→
$5.0M
Total raised · real
1
Rounds
—
Latest step-up
Top 57%
Sector rank · raised
Series A
Latest stage · inferred · Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

SeeLife Impact 5 LLC looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.81× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
  • Within the normal band (81% of peer median) for its niche.
Active
  • Last raise 6 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

SeeLife Impact 5 LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
0.7 yr record
Peak capital year was 2025 with $5.0M across 1 filings.
Market position
ahead of 44% of Biotechnology peers
Capital scale is ahead of 44% of Biotechnology peers; modeled value is above 22% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2025: $5.0M across 1 filings.
  • Largest single filing was $5.0M on 2025-12-31.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

SeeLife Impact 5 LLC is one of 4293 Biotechnology companies tracked from DRAPER. By capital raised it ranks mid-pack (ahead of 44% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(c)
Reg D exemption
93
Investors (latest)
2025
Year incorporated
2025-12-31
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MSeries A · 2025-12-31 Raised $5.0M (real) Modeled valuation $13M (est)$5.0M$13MSeries A2025

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$12.7M
Base estimate est.
$5.5M
Conservative case
$19.5M
Upside case
$22.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
0.5 yr
Elapsed time used
0.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
0.7 yr
On record since
2025
First round
New
First-time filer
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.7× of median
This company$5.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage)▼ 0.9× of median
This company$5.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages)▼ 0.2× of median
This company$12.7M
Sector median$64.2M

Raised more than 44% of sector peers (real $). Modeled value above 22% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #100 of 157.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.6M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.5M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.7M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.2M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.3M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.2M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.9M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.8M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)SeeLife Impact 5 LLC (this company) Raised $5.0M · modeled $12.7M (est)SeeLife Impact 5 LLC
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.6M3.75×
Edesa Biotech, Inc.Series A$36.9M$58.5M3.74×
4DMedical LtdSeries A$15.0M$50.7M3.24×
Arialys Therapeutics, Inc.Series A$29.1M$49.2M3.14×
Nuclein, LLCSeries A$34.5M$48.3M3.09×
Phantom Neuro Inc.Series A$15.4M$45.7M2.92×
Circulate Health, Inc.Series A$13.0M$43.3M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.2M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.61×
ENDRA Life Sciences Inc.Series A$26.8M$40.9M2.61×
Medici Therapeutics, Inc.Series A$14.8M$39.8M2.54×
Onconetix, Inc.Series A$22.0M$37.7M2.41×
SeeLife Impact 5 LLC this companySeries A$5.0M$12.7M0.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2025-12-31$22.7M$12.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2025-12-31
    • First recorded raise — entered as Series A.
    • 93 investors on this round.
Intelligence
—
Modeled next raise
$8.0M
Modeled next size est.range $5.2M–$12.8M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ronald Eugene Wilhelm—9 other2025-12
Registry & provenance

SeeLife Impact 5 LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2102852
SEC CIK
2025
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Biometric Imaging LLCBiotechnologySeries A$5.0M$10.0Msame sector · same stage
BlueWhale Bio, Inc.BiotechnologySeries A$5.0M$14.2Msame sector · same stage
Capo Therapeutics IncBiotechnologySeries A$5.0M$10.0Msame sector · same stage
Dabs Advanced Biotech Solutions LLCBiotechnologySeries A$5.0M$10.0Msame sector · same stage
DNX BiopharmaceuticalsBiotechnologySeries A$5.0M$10.0Msame sector · same stage
Global Business Development Solutions,Inc.BiotechnologySeries A$5.0M$10.0Msame sector · same stage
Luoxis Diagnostics, Inc.BiotechnologySeries A$5.0M$10.0Msame sector · same stage
Rebuilder Medical Technologies IncBiotechnologySeries A$5.0M$10.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
SeeLife Impact 1 LLCBiotechnologySeries A$12.7M98%
SeeLife Impact 4 LLCBiotechnologySeries A$12.7M97%
SeeLife Impact 3 LLCBiotechnologySeries A$12.7M97%
SeeLife Impact 6 LLCBiotechnologySeries A$12.7M97%
SeeLife Impact 2 LLCBiotechnologySeries A$12.7M97%
Sight Sciences, Inc.BiotechnologySeries B$778.7M86%
Seer Biosciences, Inc.BiotechnologySeries A$216.9M86%
Seeing Medicines, Inc.BiotechnologySeries A$158.6M84%
Frequently asked
How much funding has SeeLife Impact 5 LLC raised?
SeeLife Impact 5 LLC has raised approximately $5.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is SeeLife Impact 5 LLC's estimated valuation?
Provath's modeled valuation for SeeLife Impact 5 LLC is approximately $12.7M (modeled range $5.5M–$19.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is SeeLife Impact 5 LLC at?
SeeLife Impact 5 LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Dec 31.
What does SeeLife Impact 5 LLC do and where is it based?
SeeLife Impact 5 LLC operates in the Biotechnology sector, based in DRAPER.
Explore related

See where SeeLife Impact 5 LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at SeeLife Impact 5 LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.